The Biomedical Data Translator is now publicly available, offering a powerful open-source platform that integrates diverse biomedical datasets. Designed to accelerate discovery and patient care, Translator helps users explore complex data and uncover actionable insights with ease.
Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.
ISB hosted a full-day symposium – titled Resonance – celebrating the life and scientific contributions of Professor Ilya Shmulevich, who passed away in April 2024 from complications of acute myeloid leukemia.
CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.
ISB’s computational and bioinformatics teams played a central role in the completion of the PanCancer Atlas Initiative, the final phase of TCGA. The culmination of this work is being published in 27 papers this week across the Cell Press research journals, including “The Immune Landscape of Cancer” in Immunity.
Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.
Institute for Systems Biology, Google and CSRA have jointly created a cloud-based platform that allows researchers to quickly, reliably and securely access massive amounts of data in ways that, until now, haven’t been possible.
In a study published in PLoS Computational Biology, researchers at the Institute for Systems Biology (ISB) have developed a multiscale mutation clustering algorithm (M2C) that identifies variable length regions with high mutation density in cancer genes.